

Lumula

## Chemical Properties

CAS No. :

Formula:

Molecular Weight:

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

## Biological Description

### Description

There are currently four prostaglandin (PG) derivatives which have been approved for human clinical use for the treatment of glaucoma. The names of the PGs and the concentrations of the approved doses are: travoprost (40 µg/ml), latanoprost (50 µg/ml), bimatoprost (300 µg/ml), and unoprostone (1,500 µg/ml). All of these compounds are modified at C-1 in order to act as lipophilic prodrugs in the eye. All have also been postulated to function via activation of the prostanoid FP receptor. Unoprostone and bimatoprost stand out in this class due to their lack of potency. Both are also claimed to have alternate mechanisms of actions: as a "docosanoid" in the case of unoprostone and as a "prostamide" in the case of bimatoprost. Lumula is a hybrid eicosanoid analog which incorporates the "docosanoid" features of unoprostone as well as the "prostamide" features of bimatoprost. Based on classical structure-activity relationships which have been established for prostanoid receptors

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286    E\_mail: info@targetmol.com    Address: 36 Washington Street, Wellesley Hills, MA 02481